GlassScriptPhysician profile
Yiqing Xu
NPI 1245292333
$47,421.63
in general payments reported to CMS, 2019-2025
42 companies · $5,258 in 2025
The $5,258 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $8,263 · 2021: $3,351 · 2022: $8,866 · 2023: $3,201 · 2024: $7,323 · 2025: $5,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,468 · Food and Beverage: $7,293 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,467.50 |
| Food and Beverage | $7,293.14 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13,134.95 | 2019-2025 | Tagrisso, Enhertu, Imfinzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,422.61 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $5,615.88 | 2019-2023 | Tavalisse, Rezlidhia |
| Eisai INC. | $5,578.14 | 2020-2025 | |
| Seagen INC. | $2,336.93 | 2022-2023 | Adcetris |
| Abbvie INC. | $2,274.67 | 2020-2025 | |
| Springworks Therapeutics, INC. | $2,116.63 | 2024-2025 | Ogsiveo |
| Daiichi Sankyo INC. | $1,533.93 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Takeda Pharmaceuticals U.S.A., INC. | $875.20 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Merck Sharp & Dohme LLC | $814.95 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $802.38 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Novartis Pharmaceuticals Corporation | $734.89 | 2019-2025 | |
| Exelixis INC. | $534.52 | 2019-2025 | Cabometyx |
| Beigene USA, INC. | $525.00 | 2021-2023 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $382.54 | 2019-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $287.42 | 2019-2025 | Vyloy |
| Stemline Therapeutics INC. | $250.00 | 2024-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $247.95 | 2019-2025 | Opdivo |
| Amgen INC. | $188.22 | 2019-2021 | |
| Pfizer INC. | $174.36 | 2019-2024 | |
| Genmab U.S., INC. | $171.15 | 2022-2024 | Epkinly, Tivdak |
| Incyte Corporation | $142.34 | 2021-2025 | Monjuvi, Pemazyre, Zynyz |
| Genzyme Corporation | $130.57 | 2022-2024 | |
| Beone Medicines USA, INC. | $125.00 | 2025 | Brukinsa |
| Genentech USA, INC. | $116.41 | 2022-2025 | Venclexta, Tecentriq |
| Glaxosmithkline, LLC. | $115.19 | 2024-2025 | Zejula, Jemperli |
| Puma Biotechnology, INC. | $113.70 | 2019-2025 | |
| Sobi, INC | $85.74 | 2022 | |
| Deciphera Pharmaceuticals INC. | $82.42 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Agios Pharmaceuticals, INC. | $68.69 | 2024-2025 | Pyrukynd |
| Lilly USA, LLC | $57.02 | 2019 | |
| Sumitomo Pharma America, INC. | $48.77 | 2024 | Orgovyx |
| Tersera Therapeutics LLC | $47.18 | 2019 | |
| Emd Serono, INC. | $41.74 | 2019 | |
| Servier Pharmaceuticals LLC | $39.78 | 2025 | |
| Taiho Oncology, INC. | $37.85 | 2019-2024 | |
| Blueprint Medicines Corporation | $36.16 | 2024 | Ayvakit |
| Gilead Sciences, INC. | $32.76 | 2023 | |
| Syndax Pharmaceuticals, INC. | $32.33 | 2025 | Revuforj |
| Alexion Pharmaceuticals, INC. | $29.42 | 2025 | Ultomiris |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Celgene Corporation | $15.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yiqing Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.